MARKET NEWS

Calithera Biosciences Initiates Phase 1/2 Trial; Part of Pfizer Collaboration
Race Oncology Files IND With FDA for Cancer Drug
Skyrizi Approval in Japan Crucial for AbbVie as Biosimilar Competition Looms Large on Humira
Novel Compound for Treating TBI Demonstrates Positive Results
Swedish Biomimetics 3000 Ltd Invents Groundbreaking Continuous Peptide Manufacturing Process
ExCellThera Announces Clearance by FDA & Health Canada for New Clinical Trials

  FEATURED EDITORIAL

  COMPANY PROFILE

We aim to simplify formulation decisions that minimize attrition rates and shorten the drug development path. For existing drugs that could benefit from improved dosing, better patient compliance, or extension of product life cycle, we emphasize innovative formulation technologies. For new drug entities that suffer from solubility and bioavailability issues, we focus on guidance for pre-formulation decisions that may be combined with innovative drug delivery approaches. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Autolus Therapeutics Unveils Next-Generation Technology & Pipeline

Autolus Therapeutics Unveils Next-Generation Technology & Pipeline

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, recently presented insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development.

Saama Closes -Million Financing; Driving Disruption in Clinical Analytics & Drug Development

Saama Closes $40-Million Financing; Driving Disruption in Clinical Analytics & Drug Development

Saama Technologies, Inc., a leading clinical data analytics platform firm, announced that it has closed a $40 million financing with Perceptive Advisors.

Amyris Delivers on First CBD Milestone; Collaboration Worth 0 Million

Amyris Delivers on First CBD Milestone; Collaboration Worth $300 Million

Amyris, Inc. recently announced it successfully delivered on its first milestone for its cannabinoid partner, LAVVAN, earning its first payment of $10 million, which is part of a $300-million collaboration before future royalty payments.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 10 – Excipients
April 11 – Prefilled Syringes